Benefits and Risks of Antiviral Treatment during Pregnancy in Patients with Chronic Hepatitis B
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Lee, Yoon Seok | - |
dc.contributor.author | Bang, Soo Min | - |
dc.contributor.author | Lee, Young-Sun | - |
dc.date.accessioned | 2021-11-18T20:40:30Z | - |
dc.date.available | 2021-11-18T20:40:30Z | - |
dc.date.created | 2021-08-30 | - |
dc.date.issued | 2021-06 | - |
dc.identifier.issn | 2077-0383 | - |
dc.identifier.uri | https://scholar.korea.ac.kr/handle/2021.sw.korea/127914 | - |
dc.description.abstract | Hepatitis B virus (HBV) is a main cause of chronic liver disease worldwide and can lead to severe liver diseases. The World Health Organization has planned to eliminate viral hepatitis, including hepatitis caused by HBV and hepatitis C virus, by 2030. As mother-to-child transmission (MTCT) of HBV is a main cause of chronic HBV infection, MTCT prevention is the main target to reduce the risk of chronic HBV infection and eliminate the disease. Recent clinical trials and meta-analyses found that antiviral therapy could prevent MTCT effectively in mothers with >= 200,000 IU/mL of HBV DNA, in combination with serial vaccination and hepatitis B immune globulin administration in infants. Despite the preventive role of antivirals for MTCT of HBV, there are several concerns regarding antiviral therapy with respect to the safety of the mother and fetus during pregnancy. This review summarizes the benefits and risks of antiviral treatment during pregnancy in women with chronic HBV infection. | - |
dc.language | English | - |
dc.language.iso | en | - |
dc.publisher | MDPI | - |
dc.subject | TO-CHILD TRANSMISSION | - |
dc.subject | HBV INTRAUTERINE TRANSMISSION | - |
dc.subject | VERTICAL TRANSMISSION | - |
dc.subject | PERINATAL TRANSMISSION | - |
dc.subject | VIRAL-HEPATITIS | - |
dc.subject | VIRUS INFECTION | - |
dc.subject | E-ANTIGEN | - |
dc.subject | MOTHER | - |
dc.subject | TENOFOVIR | - |
dc.subject | TELBIVUDINE | - |
dc.title | Benefits and Risks of Antiviral Treatment during Pregnancy in Patients with Chronic Hepatitis B | - |
dc.type | Article | - |
dc.contributor.affiliatedAuthor | Lee, Young-Sun | - |
dc.identifier.doi | 10.3390/jcm10112320 | - |
dc.identifier.scopusid | 2-s2.0-85111489687 | - |
dc.identifier.wosid | 000660194000001 | - |
dc.identifier.bibliographicCitation | JOURNAL OF CLINICAL MEDICINE, v.10, no.11 | - |
dc.relation.isPartOf | JOURNAL OF CLINICAL MEDICINE | - |
dc.citation.title | JOURNAL OF CLINICAL MEDICINE | - |
dc.citation.volume | 10 | - |
dc.citation.number | 11 | - |
dc.type.rims | ART | - |
dc.type.docType | Review | - |
dc.description.journalClass | 1 | - |
dc.description.journalRegisteredClass | scie | - |
dc.description.journalRegisteredClass | scopus | - |
dc.relation.journalResearchArea | General & Internal Medicine | - |
dc.relation.journalWebOfScienceCategory | Medicine, General & Internal | - |
dc.subject.keywordPlus | TO-CHILD TRANSMISSION | - |
dc.subject.keywordPlus | HBV INTRAUTERINE TRANSMISSION | - |
dc.subject.keywordPlus | VERTICAL TRANSMISSION | - |
dc.subject.keywordPlus | PERINATAL TRANSMISSION | - |
dc.subject.keywordPlus | VIRAL-HEPATITIS | - |
dc.subject.keywordPlus | VIRUS INFECTION | - |
dc.subject.keywordPlus | E-ANTIGEN | - |
dc.subject.keywordPlus | MOTHER | - |
dc.subject.keywordPlus | TENOFOVIR | - |
dc.subject.keywordPlus | TELBIVUDINE | - |
dc.subject.keywordAuthor | antivirals | - |
dc.subject.keywordAuthor | hepatitis B virus | - |
dc.subject.keywordAuthor | mother-to-child transmission | - |
dc.subject.keywordAuthor | pregnancy | - |
dc.subject.keywordAuthor | tenofovir | - |
dc.subject.keywordAuthor | safety | - |
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.
(02841) 서울특별시 성북구 안암로 14502-3290-1114
COPYRIGHT © 2021 Korea University. All Rights Reserved.
Certain data included herein are derived from the © Web of Science of Clarivate Analytics. All rights reserved.
You may not copy or re-distribute this material in whole or in part without the prior written consent of Clarivate Analytics.